Jade Biosciencesの空売り状況は、投資家がJade Biosciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Jade Biosciences (NASDAQ:JBIO) 株価情報, 空売り情報

Jade Biosciences

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Jade Biosciences Inc

In the current market session, Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) share price is at $77.89, after a 0.84% drop. Over the past month, the stock spiked by 1.38%, but over the past year, it actually fell by 3.53%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1748642422_0.png" alt="Past Year Chart" />

<h3>Principal Financial Group P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Principal Financial Group has a better P/E ratio of 16.82 than the aggregate P/E ratio of 13.53 of the Insurance industry. Ideally, one might believe that Principal Financial Group Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748642422_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: Principal Financial Group

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) has outperformed the market over the past 20 years by 1.42% on an annualized basis producing an average annual return of 9.7%. Currently, Constellation Brands has a market capitalization of $31.79 billion. 
Buying $100 In STZ: If an investor had bought $100 of STZ stock 20 years ago, it would be worth $634.94 today based on a price of $178.58 for STZ at the time of writing.
<h3>Constellation Brands's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748642418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-05-30/trump-officials-set-for-talks-with-asia-leaders-on-alaska-energy?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/trump-officials-set-for-talks-with-asia-leaders-on-alaska-energy?embedded-checkout=true</a>

General

'Trump Officials Set for Talks With Asia Leaders on Alaska Energy'- Bloomberg

SBET

SharpLink Gaming Files For Mixed Shelf Offering; Size Not Disclosed

CELU

Celularity Receives Nasdaq Letter Regarding Form 10-Q

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) has outperformed the market over the past 15 years by 5.91% on an annualized basis producing an average annual return of 18.07%. Currently, Salesforce has a market capitalization of $253.42 billion. 
Buying $1000 In CRM: If an investor had bought $1000 of CRM stock 15 years ago, it would be worth $11,841.59 today based on a price of $265.08 for CRM at the time of writing.
<h3>Salesforce's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748640629_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

<ul>
<li>Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented</li>
<li>[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatment</li>
<li>Four of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject to confirmation.</li>
<li>Seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up</li>
<li>Perspective will hold a conference call on Monday, June 2, 2025 at 8:00 am ET &nbsp;</li>
</ul>

Biotech

CATX

Perspective Therapeutics Reveals New Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET At The 2025 ASCO Annual Meeting

LION

Liberty 77 Capital Reports 12.6% Stake In Lionsgate Studios As Of May 28 Vs Prior Stake Of 9.5% As Of May 6

CTXR

Citius Pharmaceuticals Not In Compliance With Nasdaq Minimum Bid Price

CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), a leading provider of online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, announced today that CoStar Group and Happening Technology have concluded their dispute, with all parties withdrawing every claim with prejudice, bringing the matter to a final and amicable close.
Guy Wolcott, a serial entrepreneur, founded the successful residential real estate platform Homesnap in 2012, which CoStar Group acquired in 2020 for $250 million. At the time of the acquisition, Homesnap was used regularly by over 300,000 residential agents in the United States. After departing CoStar, Wolcott, Thomas Goff, and Jeff Repanich launched Happening Technology to develop an innovative data pipeline product, with former Homesnap CEO John Mazur later becoming an investor and board member. Similarities between this product and CoStar's internal data pipeline technology prompted CoStar's reasonable concern regarding potential trade secret misappropriation — concerns that have now been fully addressed. Following a thorough review, the parties concluded that neither Happening Technology nor Wolcott, Goff, Repanich, or Mazur misappropriated CoStar's trade secrets or violated any other legal obligation.
CoStar Group and Happening Technology are pleased to put this matter behind them and are open to exploring potential opportunities for collaboration in the future.

Legal

CSGP

CoStar Group And Happening Technology Resolve Trade Secret Dispute Amicably With All Claims Withdrawn; No Misappropriation Found As Parties Close Case And Express Openness To Future Collaboration

W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) has outperformed the market over the past 20 years by 7.9% on an annualized basis producing an average annual return of 16.18%. Currently, W.W. Grainger has a market capitalization of $52.39 billion. 
Buying $100 In GWW: If an investor had bought $100 of GWW stock 20 years ago, it would be worth $2,014.00 today based on a price of $1087.60 for GWW at the time of writing.
<h3>W.W. Grainger's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748639712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In W.W. Grainger 20 Years Ago Would Be Worth Today

<h2 class="wp-block-heading">Zinger Points:</h2>
<ul class="wp-block-list">
<li>Crusoe secures $11.6 billion to build OpenAI's massive 1.2 gigawatt Abilene, Texas data center, part of the $500 billion Project Stargate.</li>
<li>Oracle has signed a 15-year lease to anchor the Abilene data center.</li>
<li>Crusoe's evolution from gas-powered crypto rigs to liquid-cooled AI supercenters captures the arc of next-gen computing.</li>
</ul>
AI infrastructure startup Crusoe Energy Systems has secured $11.6 billion in funding commitments to build a massive data center in Abilene, Texas, designed to support OpenAI's expanding computing needs. The new funding round, backed by Blue Owl Capital's Real Assets platform and Primary Digital Infrastructure, brings total capital raised for the project to $15 billion, The <a href="https://www.wsj.com/tech/ai/openai-data-center-funding-microsoft-75e879b6">Wall Street Journal </a>reported.
<h2 class="wp-block-heading">Abilene: The Heart of OpenAI&#8217;s Infrastructure Expansion</h2>
According to <a href="https://crusoe.ai/newsroom/crusoe-expands-ai-data-center-campus-in-abilene-to-1-2-gigawatts/">Crusoe</a>, the facility marks a critical step in OpenAI's infrastructure strategy. Initially planned as a two-building campus, the project now spans eight buildings. It is expected to deliver 1.2 gigawatts of power capacity, making it one of the largest AI training hubs globally.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
According to the company, construction began last June, with the first two buildings—totaling 200 megawatts—expected to be energized in the first half of this year. A second phase, launched in March, will add six more buildings and is expected to be completed by mid-2026.
<h2 class="wp-block-heading">Oracle Steps In as Microsoft's Footprint Shrinks</h2>
The expansion comes amid growing demand for compute capacity as OpenAI develops increasingly advanced artificial intelligence models. Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has signed a 15-year lease to occupy a significant portion of the Abilene campus, according to the Journal.&nbsp;
While Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) remains OpenAI's largest investor and retains exclusive application programming interface licensing rights, its role in the Abilene project is limited to that of a technology partner, without direct equity involvement. OpenAI has increasingly sought to diversify its infrastructure partnerships, citing concerns over Microsoft's ability to scale fast enough to meet its compute needs, the Journal reported.
Meanwhile, JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has committed over $7 billion to the data center project, building on a previous $2.3 billion investment, according to <a href="https://www.theinformation.com/articles/jpmorgan-lend-7-billion-openai-data-center">The Information</a>.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Project Stargate: A $500B Vision For AI Infrastructure</h2>
The Abilene project is part of &#8220;Project Stargate,&#8221; a $500 billion global AI infrastructure initiative launched in January by OpenAI, Oracle, SoftBank, and United Arab Emirates-based MGX, <a href="https://www.forbes.com/sites/emilsayegh/2025/01/22/stargate-ai-project-the-500-billion-gamble-to-dominate-the-future/">Forbes</a> reported. The project aims to build a vast network of AI data centers over the next four years to support rapid model development and increase U.S. leadership in artificial intelligence.
According to <a href="https://crusoe.ai/newsroom/crusoe-blue-owl-capital-and-primary-digital-infrastructure-enter-joint-venture">Crusoe</a>, the buildings planned in Abilene are designed for industry-scale performance, with each capable of running up to 50,000 GB200 NVL72 chips from Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) on a unified network fabric.
<h2 class="wp-block-heading">Economic and Environmental Considerations</h2>
Beyond scale, the Abilene campus is also a model for energy-conscious AI infrastructure. It incorporates direct-to-chip liquid cooling to manage thermal loads and partners with Lancium's Clean Campus program to integrate renewable energy sources, <a href="https://crusoe.ai/newsroom/crusoe-expands-ai-data-center-campus-in-abilene-to-1-2-gigawatts/">Crusoe</a> said. Crusoe expects the project to create over 5,000 jobs and generate more than $1 billion in local economic impact over the next two decades.
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Crusoe's Strategic Shift</h2>
Founded in 2018, Denver-based Crusoe began as a company converting stranded natural gas into energy for crypto mining. In recent years, it has repositioned itself as a vertically integrated AI infrastructure provider, with a sharp focus on sustainable, high-density compute environments, according to <a href="https://news.crunchbase.com/ai/startup-crusoe-financing-openai-data-center-texas/">Crunchbase</a>.
The <a href="https://www.benzinga.com/24/12/42476730/peter-thiels-founders-fund-leads-600m-crusoe-investment-betting-big-on-ai-infrastructure">company raised $600 million</a> in Series D funding led by Founders Fund, with participation from Fidelity and Nvidia, bringing its valuation to $2.8 billion. The Abilene project represents Crusoe's most ambitious venture to date and positions it at the center of the rapidly expanding AI infrastructure race.
Read Next: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a>
Image: Shutterstock

Personal Finance

MSFT

NVDA

ORCL

OpenAI Secures $11.6B For Texas Data Center Expansion, Reducing Microsoft Dependence

A recent Reddit post from a frustrated husband in the r/Dave Ramsey <a href="https://www.reddit.com/r/DaveRamsey/comments/1kt761y/can_someone_confirm_my_wifes_spending_is/">subreddit</a> caught people&#8217;s attention after asking if his wife's spending habits were out of line. His main complaint? Over the last 90 days, the family spent $6,769 on dining out alone.
&#8220;Luckily we are positive net worth,&#8221; he wrote. &#8220;But she is delaying our retirement saying her spending is normal for having 2 kids. I cover probably 80-90% of essentials from my side.&#8221;
According to his breakdown, they also spent $1,330 on groceries during the same period, along with $1,230 on supplies, $1,250 on healthcare, $560 on gas, and $1,200 on other expenses.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Reddit Reacts: &#8216;That&#8217;s Almost $30K a Year&#8217;</h2>
The response was swift and nearly unanimous. One commenter was particularly direct: &#8220;Dining out isn't just delusional, <a href="https://www.benzinga.com/personal-finance/25/02/43602320/70-year-old-with-0-saved-for-retirement-still-works-physically-demanding-job-dave-ramsey-says-eating-out-is-causing-you-to-clean-toilets">it's irresponsible</a> and incredibly selfish. That's almost $30k a year.&#8221; They also pointed out that if they placed that money with a financial advisor, &#8220;at $2k a month, and they earned an average of 12%, you have almost $650k in 15 years.&#8221;
Another person added their own math of how much they could get over 30 years if they invested that money: &#8220;$6769 was for 3 months, so $27k/year. Turns into $3 mil in 30 years at 8%.&#8221;
Others were comparing themselves: &#8220;We make $380k a year and eat out about $500/month. That dining out number is terrifying.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">&#8216;Stop Saying &#8220;I Cover Most of the Bills&#8221;&#8216;</h2>
While many were focused on the spending itself, others pushed the husband to reconsider how he approached the issue.
&#8220;Stop saying ‘I cover most of the bills&#8230;' you are we,&#8221; one person said, pointing to the importance of shared financial responsibility in a marriage, something Dave Ramsey often <a href="https://www.benzinga.com/personal-finance/25/02/43768530/should-married-couples-split-expenses-dave-ramsey-says-no-youre-married-not-roommates">teaches and preaches</a>.
Another chimed in with, &#8220;This reads more like a marriage issue than a money issue. Does she handle all of the child rearing and housework? Get off the spreadsheet and be the partner your wife needs and communicate through this issue.&#8221;
Still, others called for practical changes instead of blame. &#8220;Cut dining out to a quarter of that and add 1-2 grand to groceries and cook more – problem solved.&#8221;
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Context Matters</h2>
Many asked for more context, like income and lifestyle. Some speculated that the high numbers may be inflated by convenience apps like DoorDash. The original poster later clarified that his wife eats out &#8220;2x a day at nice restaurants always with extra appetiser or entree with some meal for kids.&#8221;
Another commenter couldn't believe it: &#8220;That is not normal. Eating out is luxury, a treat. Eating out twice a day is not normal. She is choosing eating out over your future.&#8221;
Others shared how they made it work. &#8220;We make $240k a year and it was our New Year's resolution to eat out once a month,&#8221; one user wrote. &#8220;We spend maybe $100/month eating out and that&#8217;s because we&#8217;re trying.&#8221;
In the end, what this comes down to is that the spending problem the poster has isn't just about dollars and cents. &#8220;Delusional is not a word to use if you want to have a happy marriage,&#8221; one person advised. &#8220;Some work to be done on spending and discussing spending.&#8221;
Read Next:
<ul class="wp-block-list">
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

A Husband Asks, 'Can Someone Confirm My Wife's Spending Is Delusional?' He Points To $6,769 Spent On Dining Out In Just 90 Days

Management

RETO

On May 25, ReTo Eco-Solutions Hengfang Li Tendered Resignation As CEO And Director; Co. Appointed Xinyang Li To Serve As CEO

Asset Sales

APLD

Applied Digital Discussing Possible Sale Of Cloud Services Business; Cloud Services Business To Be Reported As Discontinued Operations

BBLG

Bone Biologics Approves Plan Amendment To Increase Shares By 30M

Offerings

ADAG

Adagene Files For Offering Of Up To $100M American Depositary Shares Representing Ordinary Shares

SharpLink Gaming Announces Private Placement Offering Of ~58.7M Shares Of Common Stock And Pre-Funded Warrants At $6.15 Per Share; CEO and CFO Participate With $200K Combined Investment

<h3>Gainers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock increased by 6.8% to $0.48 during Friday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>Venu Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VENU#AMEX">VENU</a>) shares moved upwards by 6.55% to $9.98. The market value of their outstanding shares is at $378.3 million. </li>
<li>FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATBP#NASDAQ">FATBP</a>) stock rose 5.8% to $2.37. </li>
<li>GEN Restaurant Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) shares moved upwards by 4.84% to $3.46. The market value of their outstanding shares is at $17.4 million. </li>
<li>Fossil Group, Inc. - 7% Senior Notes due 2026 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSLL#NASDAQ">FOSLL</a>) stock increased by 4.59% to $16.61. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) stock increased by 4.38% to $0.51. The market value of their outstanding shares is at $12.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) stock decreased by 17.3% to $6.78 during Friday's after-market session. The market value of their outstanding shares is at $180.9 million. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares declined by 8.67% to $4.11. The company's market cap stands at $836.6 million. </li>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares declined by 7.7% to $1.32. The market value of their outstanding shares is at $39.8 million. </li>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares declined by 5.5% to $2.75. The company's market cap stands at $12.5 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares decreased by 4.84% to $73.0. The company's market cap stands at $50.9 million. </li>
<li>High Roller Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#AMEX">ROLR</a>) stock fell 4.82% to $4.15. The market value of their outstanding shares is at $34.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMST

FATBP

FLYE

Fossil Group, Inc. - 7% Senior Notes due 2026

FOSLL

FTEL

GENK

LOGC

LVWR

ROLR

TLYS

VENU

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares rose 32.5% to $0.38 during Friday's after-market session. The market value of their outstanding shares is at $2.2 million. As per the press release, Q1 earnings came out today. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) shares rose 15.99% to $34.38. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) stock moved upwards by 10.52% to $16.49. The company's market cap stands at $1.4 billion. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares moved upwards by 10.16% to $0.66. The market value of their outstanding shares is at $106.8 million. </li>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 8.38% to $1.55. The market value of their outstanding shares is at $57.7 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) shares increased by 8.37% to $3.75. The market value of their outstanding shares is at $118.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 29.6% to $0.01 during Friday's after-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock fell 15.69% to $4.14. The market value of their outstanding shares is at $3.0 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 11.63% to $0.38. The market value of their outstanding shares is at $1.8 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares fell 10.53% to $5.44. The market value of their outstanding shares is at $102.1 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 8.74% to $0.94. The company's market cap stands at $8.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 8.44% to $0.44. The market value of their outstanding shares is at $8.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

BTMD

ENTO

INTS

IRWD

KYMR

LGMK

LQDA

PSTV

RSLS

SLXN

12 Health Care Stocks Moving In Friday's After-Market Session

Press Releases

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

Earnings

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

Jade Biosciences

空売り

Jade Biosciences (NASDAQ:JBIO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル